Stock Price, News, Quote and Profile of SOL-GEL TECHNOLOGIES LTD(NASDAQ:SLGL) stock

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (12/23/2024, 2:51:29 PM)

After market: 0.4746 +0.03 (+7.84%)

0.4401

+0.01 (+2.59%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%95.24%

Sales Q2Q%2416.9%

CRS4.32

6 Month-48.31%

Overview

Earnings (Last)11-15 2024-11-15/bmo

Earnings (Next)N/A N/A

Ins Owners0.31%

Inst Owners26.44%

Market Cap12.26M

Shares27.86M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts82.5

Short Float %0.52%

Short Ratio0.9

IPO02-01 2018-02-01

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.